Platelet-Rich-Plasma Injections in Treating Lateral Epicondylosis: a Review of the Recent Evidence

Author: Murray et al
Year: 2015

The Regenerative Clinic's view on this research

Mr Ali Noorani “A review article published in 2015 by Murray et al looked at platelet rich-plasma treating lateral epicondylitis (tennis elbow). This review compared all the important evidence up to date. They concluded that after a review of literature PRP injections have an important and effective role in treatment of chronic lateral epicondylitis in cases where physiotherapy has been unsuccessful. They note that PRP has been shown to provide a continuing long-term benefit in cases of chronic epicondylitis in recent literature. It is confirmed to be superior to other injections including placebo/dry needling procedures. They also concluded that PRP has very few complications and very few adverse reactions compared to other treatments. They noted that surgery does offer good results for chronic lateral epicondylitis however surgery is not without risk in terms of scars, infection, neurovascular problems as well as instability. Therefore, if PRP could be used as an alternative then the author strongly felt that this option would present a safer option for patients and may offer a more cost-effective alternative to the health care system.”


Lateral epicondylosis is common, with various treatment modalities. Platelet—rich—plasma injections from autologous blood have recently been used in centres worldwide for the treatment of tennis elbow. We review and present the recent published evidence on the effectiveness of PRP injections for lateral epicondylosis. Nine studies met our inclusion criteria including 6 RCT’s for the purpose of analysis. PRP injections have an important and effective role in the treatment of this debilitating pathology, in cases where physiotherapy has been unsuccessful.

Get in touch

Find your clinic

We offer appointments nationwide and now working with partners abroad providing cutting edge Regenerative Medicine to patients in UK, Italy, Australia, Spain and Pakistan.